574 results on '"Tonini, Gian Paolo"'
Search Results
2. LIN28B increases neural crest cell migration and leads to transformation of trunk sympathoadrenal precursors
3. Calcium phosphate scaffolds with defined interconnecting channel structure provide a mimetic 3D niche for bone marrow metastasized tumor cell growth
4. Genetic predisposition and chromosome instability in neuroblastoma
5. TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy
6. Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib
7. Neuroblastoma (Peripheral neuroblastic tumours)
8. List of Contributors
9. Autophagy and Novel Therapeutic Strategies in Neuroblastoma
10. Data from Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors
11. Data from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
12. Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
13. Supplementary Table 2 from Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors
14. Supplementary Table 1 from Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors
15. Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
16. Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
17. Translational Downregulation of HSP90 Expression by Iron Chelators in Neuroblastoma Cells
18. Genome-Wide Analysis and Gene Expression Profiling of Neuroblastoma: What Contribution Did They Give to the Tumor Treatment?
19. Correction to: LIN28B increases neural crest cell migration and leads to transformation of trunk sympathoadrenal precursors
20. Supplementary Table 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
21. Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
22. Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
23. Supplementary Table 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
24. Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
25. Supplementary Figure 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
26. Supplementary Data from Somatic Mutations Enriched in Cis-Regulatory Elements Affect Genes Involved in Embryonic Development and Immune System Response in Neuroblastoma
27. Supplementary Figure from Somatic Mutations Enriched in Cis-Regulatory Elements Affect Genes Involved in Embryonic Development and Immune System Response in Neuroblastoma
28. Data from Somatic Mutations Enriched in Cis-Regulatory Elements Affect Genes Involved in Embryonic Development and Immune System Response in Neuroblastoma
29. Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
30. Supplementary Data 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
31. Supplementary Figure Legend from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
32. Data from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
33. Supplementary Methods from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
34. Supplementary Table 3 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
35. Supplementary Figure 1 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
36. Supplementary Figure 2 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
37. Supplementary Figure 4 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
38. Supplementary Table 1 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
39. Supplementary Table 2 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
40. Supplementary Figure 3 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
41. Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
42. The Origin of Neuroblastoma
43. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors
44. Transcription instability in high‐risk neuroblastoma is associated with a global perturbation of chromatin domains
45. Towards a turning point of neuroblastoma therapy
46. High Genomic Instability Predicts Survival in Metastatic High-Risk Neuroblastoma
47. The p53 Codon 72 Pro/Pro Genotype Identifies Poor-Prognosis Neuroblastoma Patients: Correlation with Reduced Apoptosis and Enhanced Senescence by the p53-72P Isoform
48. “DNA-Dressed NAnopore” for complementary sequence detection
49. Loss of 10q26.1–q26.3 in association with 7q34–q36.3 gain or 17q24.3–q25.3 gain predict poor outcome in pediatric medulloblastoma
50. Genetic Predisposition to Familial Neuroblastoma : Identification of Two Novel Genomic Regions at 2p and 12p
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.